Skip to main
ENGN

ENGN Stock Forecast & Price Target

ENGN Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 57%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

enGene Therapeutics is well-equipped to enter the gene therapy market for bladder cancer with its innovative product, detalimogene, which addresses the limitations of current treatments. However, the reliance on contract manufacturers and potential for supply chain challenges may impact the success of their product. The company has a strong financial outlook and experienced leadership, but faces regulatory obstacles and competition in the growing immunotherapy market. Overall, enGene Therapeutics shows potential for growth and success in the future.

Bears say

enGene Therapeutics is facing several challenges that could adversely affect its growth and financial stability, including the need for additional capital, potential competition in the non-muscle invasive bladder cancer (NMIBC) space, and potential safety concerns with its lead product candidate, detalimogene. Additionally, unexpected regulatory changes or competition from other gene therapy companies could hinder enGene's ability to gain market traction. The fact that enGene became publicly traded through a SPAC also adds uncertainty to its future performance. Considering these risks and challenges, there is a negative outlook on enGene Therapeutics' stock.

ENGN has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 57% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Engene Holdings Inc (ENGN) Forecast

Analysts have given ENGN a Buy based on their latest research and market trends.

According to 7 analysts, ENGN has a Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Engene Holdings Inc (ENGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.